Josh Schimmer
Stock Analyst at Evercore ISI Group
(4.02)
# 596
Out of 5,005 analysts
139
Total ratings
50.4%
Success rate
11.96%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $47.00 | +38.30% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $39.82 | +88.35% | 5 | Sep 8, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Overweight | n/a | $15.42 | - | 3 | Sep 8, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $25 | $20.68 | +20.89% | 4 | Sep 5, 2025 | |
| CABA Cabaletta Bio | Reiterates: Overweight | $15 | $2.44 | +514.75% | 2 | Sep 5, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $10 → $8 | $3.15 | +153.97% | 7 | Aug 8, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $52.86 | +79.72% | 12 | Jul 29, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $9.88 | +153.04% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $6.43 | -6.69% | 2 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $204.05 | +37.22% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.08 | +210.95% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $2.95 | +577.97% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $183.36 | +17.26% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.05 | +143.90% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $24.00 | +733.33% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $47.90 | -47.81% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.93 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $10.31 | +190.98% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.55 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.32 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $40.86 | +120.26% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.49 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $157.16 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.12 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.56 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.19 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $85.07 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.56 | +2,555.34% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $39.61 | +64.10% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $72.95 | -17.75% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $3.60 | +38.89% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $2.42 | +354.55% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $137.03 | -5.13% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $600.00 | +26.67% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $16.94 | -11.45% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $5.90 | +832.20% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.75 | +1,614.29% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.23 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $10.43 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $443.01 | -43.57% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $86.85 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $69.15 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.86 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $54.92 | -59.94% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.41 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.43 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $233.91 | -59.39% | 1 | Aug 17, 2017 |
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $47.00
Upside: +38.30%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $39.82
Upside: +88.35%
Denali Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.42
Upside: -
Septerna
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $20.68
Upside: +20.89%
Cabaletta Bio
Sep 5, 2025
Reiterates: Overweight
Price Target: $15
Current: $2.44
Upside: +514.75%
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.15
Upside: +153.97%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $52.86
Upside: +79.72%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $9.88
Upside: +153.04%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.43
Upside: -6.69%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $204.05
Upside: +37.22%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $16.08
Upside: +210.95%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.95
Upside: +577.97%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $183.36
Upside: +17.26%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.05
Upside: +143.90%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $24.00
Upside: +733.33%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $47.90
Upside: -47.81%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.93
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $10.31
Upside: +190.98%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.55
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.32
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $40.86
Upside: +120.26%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.49
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $157.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.12
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.56
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.19
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $85.07
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.56
Upside: +2,555.34%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $39.61
Upside: +64.10%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $72.95
Upside: -17.75%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $3.60
Upside: +38.89%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.42
Upside: +354.55%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $137.03
Upside: -5.13%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $600.00
Upside: +26.67%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $16.94
Upside: -11.45%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $5.90
Upside: +832.20%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.75
Upside: +1,614.29%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.23
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $10.43
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $443.01
Upside: -43.57%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $86.85
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $69.15
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.86
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $54.92
Upside: -59.94%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $14.41
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $55.43
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $233.91
Upside: -59.39%